In data of the Look AHEAD trial, the effects on CV risk factors of maintaining weight loss were compared with those of weight regain, in year 1 to 4 after a 1-year intensive lifestyle intervention.

Data of the Framingham Original and Offspring Cohorts show that parental smoking during childhood is associated with a higher AF risk, partly because offspring show higher propensity of smoking.

Large community-based study with repeated weight and height measurements shows that long-term obesity and change in BMI over time are more informative to assess AF risk than current weight.

Data of US postmenopausal women with normal BMI show that trunk fat and higher leg fat have opposing associations with CVD risk, while total body fat was not significantly related to CVD risk.

ESC 2019 In community-based studies in Colombia and Malaysia, HOPE-4 achieved reduced CV risk, better treatment adherence and healthier behavior with an intervention that targeted previously identified barriers to care.

ESC 2019 Data of the HOPE-4 and PURE studies confirm the impact of reducing common risk factors, and point at less acknowledged risk factors, such as home air pollution and educational level.

ESC 2019 Using genetic scores to assess lifelong exposure to LDL-c and SBP levels, suggests that relatively small differences in this exposure associated large proportional risk reductions.

ESC 2019 The PURE study shows that in high-income countries, cancer accounts for more deaths than CVD, while in low-income countries CVD mortality is higher, although risk factors are lower there.

The new, interactive online tool U-Prevent helps to translate trial data to information relevant to the individual patient: which treatment gives the greatest health benefits?

In the SMART population, smoking cessation after an event resulted in about 5 years longer survival and delay of recurrent events by about 10 years, compared to those who continue to smoke.

The European Association of Preventive Cardiology reviewed various online risk prediction algorithms and considers advantages and caveats, and gives guidance on which tool to use for which patient.

The LIFE-CVD model can assess 10-year and lifetime CVD risk and life-years gained free from CVD and the effect of interventions in apparently healthy people.